Metabolic and inflammatory parameters changes in schizophrenic patients during three months of treatment with long acting risperidone

被引：0
|
作者：
Karlovic, D. [1 ]
Solter, V. [1 ]
Potkonjak, J. [1 ]
机构：
[1] Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Psychiat, Zagreb, Croatia
来源：
EUROPEAN PSYCHIATRY | 2007年 / 22卷
关键词：
D O I：
10.1016/j.eurpsy.2007.01.509
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [31] Changes in Anthropometry and Biochemical Parameters after Six months of Treatment in Newly Diagnosed Schizophrenic Patients: A Prospective Study
    Rochlani, Dimpal
    Ahmad, Afzal
    Bansal, Sanjiv K.
    Lahariya, Sanjay
    Malviya, Maya
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2019, 13 (11) : BC08 - BC12
  • [32] Comparison of metabolic parameters among patients of schizophrenia on treatment with Olanzapine and Risperidone
    Singh, Archana
    Tomar, Abhay Singh
    Khess, C. R. J.
    Munda, Sanjay
    Siddiqui, Aleem
    Shivani
    INDIAN JOURNAL OF PSYCHIATRY, 2020, 62 : S96 - S96
  • [33] Parameters of immunity and level of cortisol in schizophrenic patients under long-term therapy with risperidone
    Lobacheva, O.
    Nikitina, V.
    Kornetova, E.
    Vetlugina, T.
    Semke, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S607 - S607
  • [34] Cognitive functions in schizophrenic patients responsive to risperidone after three-year treatment
    Rybakowski, L
    Drozdz, W
    Borkowska, A
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S401 - S401
  • [35] Comparison of metabolic factors by cookie test between schizophrenic patients during treatments with olanzapine or risperidone
    Sato, Y.
    Yasui-Furukori, N.
    Saito, M.
    Nakagami, T.
    Furukori, H.
    Kaneko, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 153 - 154
  • [36] Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone
    Nasrallah, HA
    Duchesne, I
    Mehnert, A
    Janagap, C
    Eerdekens, M
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (04) : 531 - 536
  • [37] Change in prepulse inhibition after switching schizophrenic patients from zuclopenthixol to long-acting injectable risperidone
    Rubio, G
    del Manzano, BA
    Ducaju, M
    Martínez-Gras, I
    Gimeno, D
    Borrel, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S475 - S475
  • [38] Risperidone Long-Acting Injection: Pharmacokinetics Following Administration in Deltoid Versus Gluteal Muscle in Schizophrenic Patients
    Thyssen, An
    Rusch, Sarah
    Herben, Virginie
    Quiroz, Jorge
    Mannaert, Erik
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1011 - 1021
  • [39] CHANGES IN THE HOSTILITY OF SCHIZOPHRENIC-PATIENTS DURING TREATMENT
    TSIANTIS, J
    BLACKBURN, IM
    LYKETSOS, GC
    BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1981, 54 (SEP): : 251 - 258
  • [40] Risperidone long-acting formulation in treatment-resistant schizophrenic patients the predictive value of plasma levels in relation to clinical response and safety
    Cerveri, G.
    Volonteri, L. S.
    De Gasperi, I.
    Papini, B.
    Papa, P.
    Mauri, M. C.
    Mencacci, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S524 - S524
12345